Erratum: A gene expression signature for high-risk multiple myeloma (Leukemia (2012) 26 (2406-2413) DOI: 10.1038/leu.2012.12);How to manage children and young adults with myeloproliferative neoplasms

Leukemia

Volumn 26, Issue 7, 2012, Pages 1452-1457

  Barbui, T ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

myeloproliferative neoplasms; treatment; young people

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HYDROXYUREA; RECOMBINANT ALPHA INTERFERON;

ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHILDHOOD CANCER; DISEASE SEVERITY; FLU LIKE SYNDROME; HUMAN; LOW DRUG DOSE; MENTAL DISEASE; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RECURRENT DISEASE; RISK MANAGEMENT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOSIS; VEIN THROMBOSIS;

EID: 84863778921     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.53     Document Type: Erratum

References (64)

1. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355: 2452-2466.
2. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011; 29: 573-582.
3. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
4. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008. revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951.
5. Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L et al. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood 2007; 110: 3384-3386.
6. Gassas A, Doyle JJ, Weitzman S, Freedman MH, Hitzler JK, Sharathkumar A et al. A basic classification and a comprehensive examination of pediatric myeloproliferative syndromes. J Pediatr Hematol Oncol 2005; 27: 192-196.
7. Nakatani T, Imamura T, Ishida H, Wakaizumi K, Yamamoto T, Otabe O et al. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia. Pediatr Blood Cancer 2008; 51: 802-805.
8. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29: 3179-3184.
9. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255-1265.
10. Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson C et al. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol 2009; 82: 255-259.
11. Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 2009; 113: 4171-4178.
12. Mallouh AA, Sa'di AR. Agnogenic myeloid metaplasia in children. Am J Dis Child 1992; 146: 965-967.
13. Bonduel M, Sciuccati G, Torres AF, Pierini A, Gallo G. Familial idiopathic myelofibrosis and multiple hemangiomas. Am J Hematol 1998; 59: 175-177.
14. Kvasnicka HM, Thiele J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost 2006; 32: 362-371.
15. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-2901.
16. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M. Increased risks of PV, ET, and PMF among 24 577 first-degree relatives of 11 039 patients with MPNs in Sweden. Blood 2008; 112: 2199-2204.
17. Rumi E, Passamonti F, Della Porta MG, Elena C, Arcaini L, Vanelli L et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 2007; 25: 5630-5635.
18. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761-770.
19. Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA et al. The JAK2 46/1 haplotype confers susceptibility to ET regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia 2010; 24: 110-114.
20. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115: 778-782.
21. Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 2005; 129: 293-306.
22. Barbui T, Finazzi G. Myeloproliferative disease in pregnancy and other management issues. Hematol Am Soc Hematol Educ Program 2006, 246-252.
23. Gangat N, Wolanskyj AP, Schwager SM, Mesa RA, Tefferi A. Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia. Cancer 2006; 106: 2406-2411.
24. Danish EH, Rasch CA, Harris JW. Polycythemia vera in childhood: case report and review of the literature. Am J Hematol 1980; 9: 421-428.
25. Cario H, McMullin MF, Pahl HL. Clinical and hematological presentation of children and adolescents with polycythemia vera. Ann Hematol 2009; 88: 713-719.
26. Mitus AJ, Barbui T, Shulman LN, Rosenthal DS, Viero P, Cortelazzo S et al. Hemostatic complications in young patients with essential thrombocythemia. Am J Med 1990; 88: 371-375.
27. Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010; 149: 352-375.
28. Barosi G, Birgegard G, Finazzi G Griesshammer M, Harrison C, Hasselbalch HC et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009; 113: 4829-4833.
29. van Genderen PJJ, Budde A, Michiels JJ, van Strik R, van Vliet HH. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythemia is related to the platelet count. Br J Haematol 1996; 93: 962-965.
30. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood 2003; 101: 3749.
31. Sekhar M, Prentice HG, Popat U, Anderson D, Janmohammed R, Roberts I et al. Idiopathic myelofibrosis in children. Br J Haematol 1996; 93: 394-397.
32. Boxer LA, Camitta BM, Berenberg W, Fanning JP. Myelofibrosis-myeloid metaplasia in childhood. Pediatrics 1975; 55: 861-865.
33. Naithani R, Tyagi S, Choudhry VP. Secondary myelofibrosis in children. J Pediatr Hematol Oncol 2008; 30: 196-198.
34. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132-143.
35. Najean Y, Rain JD. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol 1997; 34: 6-16.
36. Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R. The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007; 136: 249-259.
37. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114-124.
38. Alvarez-Larran A, Cervantes F, Pereira A, Arellano-Rodrigo E, Pérez-Andreu V, Hernández-Boluda JC et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010; 116: 1205-1210.
39. Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008-WHO-criteria. Leukemia 2011 (in press).
40. Tefferi A, Gangat N, Wolanskyj AP. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia: does number matter? Blood 2006; 108: 2493-2494.
41. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and JAK2 mutation status. Blood 2007; 109: 2310-2313.
42. Passamonti F, Malabarba L, Orlandi E, Baratè C, Canevari A, Brusamolino E et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 2003; 88: 13-18.
43. Ruggeri M, Finotto S, Fortuna S, Rodeghiero F. Treatment outcome in a cohort of young patients with polycythemia vera. Intern Emerg Med 2010; 5: 411-413.
44. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23: 2224-2232.
45. Alvarez-Larrán A, Cervantes F, Bellosillo B, Giralt M, Juliá A, Hernández-Boluda JC et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 2007; 21: 1218-1223.
46. Palandri F, Polverelli N, Ottaviani E, Castagnetti F, Baccarani M, Vianelli N. Longterm follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. Haematologica 2010; 95: 1038-1040.
47. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008; 93: 372-380.
48. Carobbio A, Finazzi G, Antonioli E, Vannucchi AM, Barosi G, Ruggeri M et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood 2010; 116: 1051-1055.
49. Bjorkholm J, Derolf AR, Ekstrand C, Kristinsson SY, Ekstrand C, Goldin LR et al. Clinical risk for AML/MDS transformation in Philadelphia negative chronic myeloproliferative neoplasms. A population-based nested case-control study in Sweden. J Clin Oncol 2011; 29: 2410-2415.
50. Kiladjian JJ, Chevret S, Dosquet C, Fenaux P, Chomienne C, Rain J-D. Long-term outcome in polycythemia vera: final analysis of a randomized trial comparing hydroxyurea (HU) to pipobroman (Pi). Blood 2008; 112 (abstract 1746).
51. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: longterm follow-up of a randomized clinical trial. Br J Haematol 2000; 110: 577-583.
52. Antonioli A, Guglielemelli P, Pieri L, Finazzi MC, Rumi E, Martinelli V et al. Side effects of hydroxyurea in classic chronic myeloproliferative neoplasms. A retrospective study of 3411 patients. Haematologica 2011; 96(suppl 2): 380 (abstract 913).
53. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M et al. Pegylated interferon alpha-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065-3072.
54. Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S et al. Pegylated interferon alpha-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27: 5418-5424.
55. Hasselbalch HC, Kiladjian JJ, Silver RT. Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. J Clin Oncol 2011; 29: e564-e565.
56. Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 2007; 21: 277-280.
57. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33-45.
58. Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relation to therapy. J Clin Oncol 2009; 27: 2991-2999.
59. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.
60. Thiele J, Kvasnicka HM, Vardiman JW, Orazi A, Franco V, Gisslinger H et al. Bone marrow fibrosis and diagnosis of essential thrombocythemia. J Clin Oncol 2009; 27: e220-e221.
61. Gisslinger H, Gotic M, Holowiecki J, Miroslav P, Juergen T, Hans MK et al. Final results of the ANAHYDRET study: non-inferiority of anagrelide compared to hydroxyurea in newly diagnosed WHO essential thrombocythemia patients. Blood 2008; 112 (abstract 661).
62. Tefferi A. Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act. Bone Marrow Transplant 2010; 45: 419-421.
63. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-1127.
64. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29: 789-796.